02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Rat and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) NEAT1 could help treat neointimal hyperplasia. In carotid artery samples from a rat model of angioplasty-associated neointimal hyperplasia, NEAT1 levels were higher...
04:17 , Oct 13, 2018 |  BioCentury  |  Product Development

Trevena goes for MOR than morphine

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee meeting on pain candidate oliceridine from Trevena Inc. gave the agency little reason to reverse its skepticism about the molecule’s benefits and risks. But it did leave...
19:27 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

ArunA’s exosome entrance

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective...
20:45 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; neurology

INDICATION: Atherosclerosis; stroke Mouse studies suggest inhibiting adenosine kinase could help treat atherosclerosis and stroke. In a mouse model of atherosclerosis, vascular endothelial cell-specific knockout of adenosine kinase decreased atherosclerotic lesion size and the necrotic...
18:18 , Sep 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Ophthalmic Cell culture and mouse studies suggest inhibiting ADORA2A could help treat proliferative retinopathy. In a mouse model of the disease, retinal levels of ADORA2A were higher than in normal mice. In human microvascular...
16:27 , Apr 25, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of IDO1 and its metabolite kynurenine , or the promoter methylation status of the IDO1 gene, could aid the differential diagnosis of breast cancer subtypes. In breast cancer cell lines,...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: WAS protein family member 3 (WASF3); NCK associated protein 1 (NCKAP1); cytoplasmic FMR1 interacting protein 1 (CYFIP1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest that inhibiting the WASF3-NCKAP1- CYFIP1 complex could help treat metastatic breast cancer. In breast cancer patients, high tumor levels of NCKAP1 were associated...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: σ-1 receptor

Ophthalmic disease INDICATION: Blindness Mouse studies suggest agonizing the σ-1 receptor could help prevent blindness caused by inherited retinal degeneration. In a mouse model of genetic retinal degeneration, the σ-1 receptor agonist (+)-pentazocine increased cone...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC); DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

Cancer INDICATION: Breast cancer Patient sample, cell and mouse studies suggest combining inhibitors of HDAC and DNMT1 could help treat breast cancer. In human and mouse breast cancer cell lines, an HDAC inhibitor tool compound...